NIKKEI 225
37,956.87 +328.39 (+0.87%) HANG SENG
17,678.16 +393.62 (+2.28%) CRUDE OIL
84.04 +0.47 (+0.56%) GOLD FUTURES
2,348.30 +5.80 (+0.25%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,589.21 +226.91 (+0.44%)
Omega Therapeutics, Inc. (OMGA)
After hours:
| Previous close | 2.3300 |
| Open | 2.2800 |
| Bid | 2.3400 x 400 |
| Ask | 2.3700 x 500 |
| Day's range | 2.2001 - 2.3700 |
| 52-week range | 1.3000 - 10.0900 |
| Volume | |
| Avg. volume | 438,091 |
| Market cap | 129.614M |
| Beta (5Y monthly) | 1.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8000 |
| Earnings date | 28 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.83 |
ZacksOmega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Omega Therapeutics (OMGA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireOmega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, MD, May 7 – 11, 2024. The poster will feature new preclinical data that demonstrate the ability of Omega's programmable epigeno
ZacksOmega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Omega Therapeutics (OMGA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
